Evidence map›Paper›PMID 27092777›Full record

ArticlePloS one2016

Utility of Serum miR-125b as a Diagnostic and Prognostic Indicator and Its Alliance with a Panel of Tumor Suppressor Genes in Epithelial Ovarian Cancer.

Mariyam Zuberi, Imran Khan, Rashid Mir, Gauri Gandhi, Prakash Chandra Ray, Alpana Saxena

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 5 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 5 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. The Role of microRNA in the Prognosis and Diagnosis of Ovarian Cancer.International journal of molecular sciences · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Mariyam ZuberiDepartment of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi, India.
Imran KhanDepartment of Surgery, University of Illinois at Chicago, Chicago, Illinois, United States of America.
Rashid MirPrince Fahd Bin Sultan Research Chair, Faculty of Applied Medical Sciences, University of Tabuk, Saudi Arabia, Tabuk-71491.
Gauri GandhiDepartment of Gynaecology and Obstetrics, Lok Nayak Hospital, New Delhi, India.
Prakash Chandra RayDepartment of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi, India.
Alpana SaxenaDepartment of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi, India.
Maulana Azad Medical College · INLok Nayak Jai Prakash Narayan Hospital · INUniversity of Illinois Chicago · USUniversity of Tabuk · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) have been found to be dysregulated in epithelial ovarian cancer (EOC) and may function as either tumor suppressor genes (TSGs) or as oncogenes. Hypermethylation of miRNA silences the tumour suppressive function of a miRNA or hypermethylation of a TSG regulating that miRNA (or vice versa) leads to its loss of function. The present study aims to evaluate the impact of aberrant microRNA-125b (miR-125b) expression on various clinicopathological features in epithelial ovarian cancer and its association with anomalous methylation of several TSGs. We enrolled 70 newly diagnosed cases of epithelial ovarian cancer, recorded their clinical history and 70 healthy female volunteers. Serum miR-125b levels were determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and the methylation status of various TSGs was investigated by methylation specific PCR. ROC curves were constructed to estimate the diagnostic and prognostic usefulness of miR-125b. The Kaplan-Meier method was applied to compare survival curves. Expression of miR-125b was found to be significantly upregulated (p<0.0001) in comparison with healthy controls. The expression level of miR-125b was found to be significantly associated with FIGO stage, lymph node and distant metastasis. ROC curve for diagnostic potential yielded significant AUC with an equitable sensitivity and specificity. ROC curves for prognosis yielded significant AUCs for histological grade, distal metastasis, lymph node status and survival. The expression of miR-125b also correlated significantly with the hypermethylation of TSGs. Our results indicate that DNA hypermethylation may be involved in the inactivation of miR-125b and miR-125b may function as a potential independent biomarker for clinical outcome in EOC.

Indexed as

Biomarkers, TumorCarcinoma, Ovarian EpithelialDisease ProgressionFemaleGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansMicroRNAsMiddle AgedNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisROC CurveUp-RegulationBiomarkers, TumorMicroRNAsMIRN125 microRNA, human

Identifiers

PMID27092777
PMCPMC4836713
OpenAlexW2338011571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.